RaySearch Celebrates Over 100 RayStation Clients in Asia

RaySearch Laboratories Achieves Remarkable Milestone

RaySearch Laboratories AB (publ) is thrilled to share that the number of radiotherapy centers utilizing RayStation for treatment planning has surpassed 100 in Asia. This remarkable achievement positions Asia as RaySearch's third largest market following the US and Japan, showcasing a strong foothold in the region's healthcare sector.

Expansion of RayStation in Asia

Since launching in 2009, RayStation has secured its place in over 1,000 cancer centers spread across 44 countries. In the US and Japan, more than 300 and 220 centers respectively are currently using this advanced system. An important step for RaySearch came with the installation of RayStation at a prominent hospital in the region, marking a significant milestone as the number of centers in Asia utilizing this innovative technology has now exceeded 100.

China Japan Friendship Hospital's Impact

The China Japan Friendship Hospital, recognized as one of the foremost hospitals in Asia, is known for its commitment to adopting cutting-edge technology and equipment. The inclusion of RayStation complements its advancements in providing proton therapy, a substantial leap forward in cancer treatment accessibility in the region.

RayStation's Versatile Treatment Planning Capabilities

As a highly adaptable and powerful treatment planning system, RayStation supports an impressive array of treatment techniques, including traditional photon radiotherapy and advanced radiotherapy technologies such as proton and carbon ion therapy. With around 120 proton centers among its clientele, RaySearch has positioned itself as the leader in the ion treatment market by continuously innovating and integrating groundbreaking functionalities into RayStation.

Leadership Perspective

Johan Löf, founder and CEO of RaySearch, expressed his excitement regarding the first RayStation order from a prestigious hospital in Asia. He highlighted the significance of having over 100 customers in the region as a crucial move for further expansion, with the vision of improving cancer care through RayStation's advanced technology and other complementary solutions.

About China Japan Friendship Hospital

Established in 1984, the China Japan Friendship Hospital is both a research and teaching institution, recognized as one of the top hospitals in Asia. With over 1,600 inpatient beds, the hospital collaborates with several prestigious medical schools and actively engages in a range of services including medical care, preventive medicine, education, and research. Its continuous investment in the latest technology underscores its commitment to providing exceptional healthcare. In recognition of its vital role, the hospital is directly linked to the Ministry of Health, having been designated as a key facility during major health crises.

About RaySearch Laboratories

RaySearch Laboratories AB (publ) specializes in developing innovative software solutions aimed at enhancing oncology treatment. Their flagship products include the RayStation treatment planning system and the oncology information systems RayCare. The latest additions to their product lineup encompass RayIntelligence, an analytics system designed to facilitate data collection and analysis, and RayCommand, a system that links various treatment components together to streamline processes.

Since its inception in 2000 as a spin-off from a leading medical institute and entering public trading in 2003, RaySearch has successfully expanded its software solutions to over 1,000 clinics in 44 countries.

About RayStation

RayStation is a highly regarded treatment planning system embraced by numerous distinguished cancer centers worldwide, featuring outstanding capabilities such as adaptive therapy and multi-criteria optimization. RayStation’s advanced algorithms facilitate superior treatment planning for various therapies, ensuring cancer centers can maximize the value gained from their existing technologies. By integrating seamlessly with RayCare, it aims to enhance patient care on a global scale.

Frequently Asked Questions

What is RaySearch Laboratories known for?

RaySearch Laboratories is recognized for developing innovative software solutions aimed at improving cancer treatment efficiency and outcomes.

How many RayStation customers are there in Asia?

RaySearch has successfully surpassed 100 RayStation customers in Asia, affirming its growing presence in this essential market.

What significant achievement did RaySearch announce recently?

RaySearch recently announced that it has achieved over 100 RayStation installations in Asia, marking a vital milestone in its expansion.

What feature sets RayStation apart from competitors?

RayStation is distinguished by its adaptability and comprehensive treatment planning capabilities for various advanced radiotherapy techniques.

What role does the China Japan Friendship Hospital play in this development?

The China Japan Friendship Hospital has significantly contributed to this achievement by adopting RayStation for its advanced cancer treatment technology.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.